Literature DB >> 28645072

Association of the serum myeloperoxidase/high-density lipoprotein particle ratio and incident cardiovascular events in a multi-ethnic population: Observations from the Dallas Heart Study.

Htet W Khine1, John F Teiber1, Robert W Haley1, Amit Khera1, Colby R Ayers1, Anand Rohatgi2.   

Abstract

BACKGROUND AND AIMS: Myeloperoxidase (MPO), a product of systemic inflammation, promotes oxidation of lipoproteins; whereas, high-density lipoprotein (HDL) exerts anti-oxidative effects in part via paraoxonase-1 (PON1). MPO induces dysfunctional HDL particles; however, the interaction of circulating levels of these measures in cardiovascular disease (CVD) has not been studied in humans. We tested whether serum levels of MPO indexed to HDL particle concentration (MPO/HDLp) are associated with increased CVD risk in a large multiethnic population sample, free of CVD at baseline.
METHODS: Levels of MPO, HDL-C, and HDL particle concentration (HDLp) by NMR were measured at baseline in 2924 adults free of CVD. The associations of MPO/HDLp with incident ASCVD (first non-fatal myocardial infarction, non-fatal stroke, coronary revascularization, or CVD death) and total CVD were assessed in Cox proportional-hazards models adjusted for traditional risk factors. The median follow-up period was 9.4 years.
RESULTS: Adjusted for sex and race/ethnicity, MPO/HDLp was associated directly with body mass index, smoking status, high-sensitivity C-reactive protein, and interleukin 18, and inversely with age, HDL-C levels, HDL size, and PON1 arylesterase activity, but not with cholesterol efflux. In fully adjusted models, the highest versus lowest quartile of MPO/HDLp was associated with a 74% increase in incident ASCVD (aHR, 1.74, 95% CI 1.12-2.70) and a 91% increase in total incident CVD (aHR, 1.91, 95% CI 1.27-2.85).
CONCLUSIONS: Increased MPO indexed to HDL particle concentration (MPO/HDLp) at baseline is associated with increased risk of incident CVD events in a population initially free of CVD over the 9.4 year period.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  HDL particle concentration; Incident cardiovascular disease; Myeloperoxidase; Paroxonase-1

Mesh:

Substances:

Year:  2017        PMID: 28645072      PMCID: PMC5557659          DOI: 10.1016/j.atherosclerosis.2017.06.007

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  42 in total

Review 1.  Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy.

Authors:  Elias J Jeyarajah; William C Cromwell; James D Otvos
Journal:  Clin Lab Med       Date:  2006-12       Impact factor: 1.935

2.  C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992.

Authors:  W Koenig; M Sund; M Fröhlich; H G Fischer; H Löwel; A Döring; W L Hutchinson; M B Pepys
Journal:  Circulation       Date:  1999-01-19       Impact factor: 29.690

3.  High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (multi-ethnic study of atherosclerosis).

Authors:  Rachel H Mackey; Philip Greenland; David C Goff; Donald Lloyd-Jones; Christopher T Sibley; Samia Mora
Journal:  J Am Coll Cardiol       Date:  2012-07-11       Impact factor: 24.094

4.  HDL cholesterol efflux capacity and incident cardiovascular events.

Authors:  Anand Rohatgi; Amit Khera; Jarett D Berry; Edward G Givens; Colby R Ayers; Kyle E Wedin; Ian J Neeland; Ivan S Yuhanna; Daniel R Rader; James A de Lemos; Philip W Shaul
Journal:  N Engl J Med       Date:  2014-11-18       Impact factor: 91.245

5.  Paraoxonase-1 activity is positively related to phospholipid transfer protein activity in type 2 diabetes mellitus: Role of large HDL particles.

Authors:  Robin P F Dullaart; Eke G Gruppen; Geesje M Dallinga-Thie
Journal:  Clin Biochem       Date:  2015-12-02       Impact factor: 3.281

6.  Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R.

Authors:  M Aviram; S Billecke; R Sorenson; C Bisgaier; R Newton; M Rosenblat; J Erogul; C Hsu; C Dunlop; B La Du
Journal:  Arterioscler Thromb Vasc Biol       Date:  1998-10       Impact factor: 8.311

7.  Myeloperoxidase level in patients with stable coronary artery disease and acute coronary syndromes.

Authors:  G Ndrepepa; S Braun; J Mehilli; N von Beckerath; A Schömig; A Kastrati
Journal:  Eur J Clin Invest       Date:  2008-02       Impact factor: 4.686

8.  Serum myeloperoxidase/paraoxonase 1 ratio as potential indicator of dysfunctional high-density lipoprotein and risk stratification in coronary artery disease.

Authors:  Yoko Haraguchi; Ryuji Toh; Minoru Hasokawa; Hideto Nakajima; Tomoyuki Honjo; Kazunori Otsui; Kenta Mori; Maki Miyamoto-Sasaki; Masakazu Shinohara; Kunihiro Nishimura; Tatsuro Ishida; Ken-Ichi Hirata
Journal:  Atherosclerosis       Date:  2014-03-19       Impact factor: 5.162

9.  Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population Study.

Authors:  Marijn C Meuwese; Erik S G Stroes; Stanley L Hazen; Joram N van Miert; Jan Albert Kuivenhoven; Robert G Schaub; Nicholas J Wareham; Robert Luben; John J P Kastelein; Kay-Tee Khaw; S Matthijs Boekholdt
Journal:  J Am Coll Cardiol       Date:  2007-06-21       Impact factor: 24.094

10.  Diminished antioxidant activity of high-density lipoprotein-associated proteins in chronic kidney disease.

Authors:  David J Kennedy; W H Wilson Tang; Yiying Fan; Yuping Wu; Shirley Mann; Michael Pepoy; Stanley L Hazen
Journal:  J Am Heart Assoc       Date:  2013-04-04       Impact factor: 5.501

View more
  6 in total

Review 1.  Oxidative Stress in Human Atherothrombosis: Sources, Markers and Therapeutic Targets.

Authors:  Jose Luis Martin-Ventura; Raquel Rodrigues-Diez; Diego Martinez-Lopez; Mercedes Salaices; Luis Miguel Blanco-Colio; Ana M Briones
Journal:  Int J Mol Sci       Date:  2017-11-03       Impact factor: 5.923

2.  Association between SLC44A4-NOTCH4 SNPs and serum lipid levels in the Chinese Han and Maonan ethnic groups.

Authors:  Peng-Fei Zheng; Rui-Xing Yin; Yao-Zong Guan; Bi-Liu Wei; Chun-Xiao Liu; Guo-Xiong Deng
Journal:  Nutr Metab (Lond)       Date:  2020-12-14       Impact factor: 4.169

Review 3.  Cholesterol Transport Dysfunction and Its Involvement in Atherogenesis.

Authors:  Anastasia V Poznyak; Dmitry A Kashirskikh; Vasily N Sukhorukov; Vladislav Kalmykov; Andrey V Omelchenko; Alexander N Orekhov
Journal:  Int J Mol Sci       Date:  2022-01-25       Impact factor: 5.923

4.  The LDL/HDL ratio predicts long-term risk of coronary revascularization in ST-segment elevation myocardial infarction patients undergoing percutaneous coronary intervention: a cohort study.

Authors:  Ruochen Zhang; Yan Fan; Yanbo Xue; Yunfei Feng; Caijuan Dong; Yamei Wang; Puqing Kou; Guoli Li; Aiqun Ma; Tingzhong Wang
Journal:  Braz J Med Biol Res       Date:  2022-02-04       Impact factor: 2.590

5.  Myeloperoxidase level and inflammatory markers and lipid and lipoprotein parameters in stable coronary artery disease.

Authors:  Elżbieta Kimak; Bartosz Zięba; Dariusz Duma; Janusz Solski
Journal:  Lipids Health Dis       Date:  2018-04-04       Impact factor: 3.876

6.  Prognostic indicators for the onset of ischaemic versus haemorrhagic stroke in stable coronary artery disease.

Authors:  Wei-Ting Wang; Tao-Cheng Wu; Wei-Kung Tseng; Yen-Wen Wu; Tsung-Hsien Lin; Hung-I Yeh; Kuan-Cheng Chang; Ji-Hung Wang; Hsin-Bang Leu; Wei-Hsian Yin; Chau-Chung Wu; Jaw-Wen Chen
Journal:  Medicine (Baltimore)       Date:  2021-12-03       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.